Subcutaneous Daratumumab Plus Carfilzomib and Dexamethasone (D-Kd) in Relapsed/Refractory Multiple Myeloma: An Open-label, Multicenter, Phase 2 Study (PLEIADES)

2019 ◽  
Vol 19 (10) ◽  
pp. e144
Author(s):  
Ajai Chari ◽  
Hartmut Goldschmidt ◽  
shiyi yang ◽  
Michele Kosh ◽  
Maria Delioukina ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Open Label ◽  
Refractory Multiple Myeloma ◽  
Multicenter Phase ◽  
Phase 2 Study

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

2020 ◽  
Vol 21 (2) ◽  
pp. 207-221 ◽  
Author(s):  
Sagar Lonial ◽  
Hans C Lee ◽  
Ashraf Badros ◽  
Suzanne Trudel ◽  
Ajay K Nooka ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Open Label ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study ◽  
Open Label Phase

Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES)

2019 ◽  
Vol 19 (10) ◽  
pp. e16-e17 ◽  
Author(s):  
Ajai Chari ◽  
Hartmut Goldschmidt ◽  
Jesus San-Miguel ◽  
Helen McCarthy ◽  
Kenshi Suzuki ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Open Label ◽  
Treatment Regimens ◽  
Multicenter Phase ◽  
Phase 2 Study
Sign in / Sign up

Export Citation Format

Share Document